Cargando…
Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel
This paper analyses self-declared aims and representation of dementia patient organizations and advocacy groups (POs) in relation to two recent upheavals: the critique of social stigmatization and biomedical research focusing on prediction. Based on twenty-six semi-structured interviews conducted in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209015/ https://www.ncbi.nlm.nih.gov/pubmed/30066235 http://dx.doi.org/10.1007/s11673-018-9871-8 |
_version_ | 1783366831174582272 |
---|---|
author | Schicktanz, Silke Rimon-Zarfaty, Nitzan Raz, Aviad Jongsma, Karin |
author_facet | Schicktanz, Silke Rimon-Zarfaty, Nitzan Raz, Aviad Jongsma, Karin |
author_sort | Schicktanz, Silke |
collection | PubMed |
description | This paper analyses self-declared aims and representation of dementia patient organizations and advocacy groups (POs) in relation to two recent upheavals: the critique of social stigmatization and biomedical research focusing on prediction. Based on twenty-six semi-structured interviews conducted in 2016–2017 with members, service recipients, and board representatives of POs in Germany and Israel, a comparative analysis was conducted, based on a grounded theory approach, to detect emerging topics within and across the POs and across national contexts. We identified a heterogeneous landscape, with the only Israeli PO focusing strongly on caretakers, whereas in Germany several POs claim to represent this patient collective. Shared aims of all POs were fighting social stigma, balancing the loss of patients’ individual autonomy, and the well-being of caretakers. By highlighting the emergence of new groups of dementia self-advocacy against the more traditional advocacy by others, this study highlights how advocacy and representation in the context of AD are embedded in the discursive context of stigmatization and revised disease conception. Future developments in early diagnosis and prediction of dementia, with more affected people likely to conduct dementia self-advocacy, might challenge existing representation structures even more. |
format | Online Article Text |
id | pubmed-6209015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-62090152018-11-13 Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel Schicktanz, Silke Rimon-Zarfaty, Nitzan Raz, Aviad Jongsma, Karin J Bioeth Inq Symposium: Collective Representation in Healthcare Policy This paper analyses self-declared aims and representation of dementia patient organizations and advocacy groups (POs) in relation to two recent upheavals: the critique of social stigmatization and biomedical research focusing on prediction. Based on twenty-six semi-structured interviews conducted in 2016–2017 with members, service recipients, and board representatives of POs in Germany and Israel, a comparative analysis was conducted, based on a grounded theory approach, to detect emerging topics within and across the POs and across national contexts. We identified a heterogeneous landscape, with the only Israeli PO focusing strongly on caretakers, whereas in Germany several POs claim to represent this patient collective. Shared aims of all POs were fighting social stigma, balancing the loss of patients’ individual autonomy, and the well-being of caretakers. By highlighting the emergence of new groups of dementia self-advocacy against the more traditional advocacy by others, this study highlights how advocacy and representation in the context of AD are embedded in the discursive context of stigmatization and revised disease conception. Future developments in early diagnosis and prediction of dementia, with more affected people likely to conduct dementia self-advocacy, might challenge existing representation structures even more. Springer Singapore 2018-07-31 2018 /pmc/articles/PMC6209015/ /pubmed/30066235 http://dx.doi.org/10.1007/s11673-018-9871-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Symposium: Collective Representation in Healthcare Policy Schicktanz, Silke Rimon-Zarfaty, Nitzan Raz, Aviad Jongsma, Karin Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel |
title | Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel |
title_full | Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel |
title_fullStr | Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel |
title_full_unstemmed | Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel |
title_short | Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel |
title_sort | patient representation and advocacy for alzheimer disease in germany and israel |
topic | Symposium: Collective Representation in Healthcare Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209015/ https://www.ncbi.nlm.nih.gov/pubmed/30066235 http://dx.doi.org/10.1007/s11673-018-9871-8 |
work_keys_str_mv | AT schicktanzsilke patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael AT rimonzarfatynitzan patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael AT razaviad patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael AT jongsmakarin patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael |